Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Fortress Biotech, Inc. (NASDAQ: FBIO).

Full DD Report for FBIO

You must become a subscriber to view this report.


Recent News from (NASDAQ: FBIO)

Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence
NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Michael G. King, Jr. has been ...
Source: GlobeNewswire
Date: May, 15 2018 08:00
Mustang Bio Reports First Quarter 2018 Financial Results
NEW YORK, May 14, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today annou...
Source: GlobeNewswire
Date: May, 14 2018 17:30
Fortress Biotech misses by $0.06, beats on revenue
Fortress Biotech (NASDAQ: FBIO ): Q1 EPS of -$0.49 misses by $0.06 . More news on: Fortress Biotech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 17:07
Fortress Biotech Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, May 10, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced financial results and recent corpor...
Source: GlobeNewswire
Date: May, 10 2018 16:15
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial results and recent corporate highlights for the first quarter en...
Source: GlobeNewswire
Date: May, 03 2018 07:30
Mustang Bio to Present at Biotech Innovations Conference
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR-T) technology, today ann...
Source: GlobeNewswire
Date: April, 04 2018 08:00
Week 14 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 14: Market conditions continue with extreme volatility. The Market Momentum Gauge indicators are now a subscription based forecasting feature to help gauge the expected momentum conditions for the week ahead. The total return of the Breakout Stock select...
Source: SeekingAlpha
Date: March, 31 2018 09:55
3 Things In Biotech, March 29: Bristol And Protagonist Opposite Day In The Colon
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 30 2018 08:00
Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today ann...
Source: GlobeNewswire
Date: March, 29 2018 16:30
Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company developing treatments for rare and life-threatening diseases, today announced a new analysis of data from the Phase 1b trial of CAEL-101 (mAb 11-1F4...
Source: GlobeNewswire
Date: March, 27 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-201.911.9011.971.85133,174
2018-08-172.011.932.01581.9165,339
2018-08-162.022.022.062.00140,077
2018-08-152.012.03692.082.00164,896
2018-08-142.142.022.18252.00134,496

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2017,52565,68026.6824Cover
2018-08-171,16018,0916.4120Cover
2018-08-166,58953,79812.2477Cover
2018-08-158,71468,60412.7019Cover
2018-08-1418,44750,02636.8748Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FBIO.


About Fortress Biotech, Inc. (NASDAQ: FBIO)

Logo for Fortress Biotech, Inc. (NASDAQ: FBIO)

We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.

 

 

 

Current Management

  • Bobby W. Sandage / President, CEO
  • Noah D. Beerman / EVP, COO
  • Dale Ritter / VP, Fin., Chief Accounting Officer, Acting CFO
  • Glenn L. Cooper / Executive Chairman
  • Eric K. Rowinsky / Vice Chairman
  • David J. Barrett /
  • Jimmie Harvey, Jr. /
  • J. Jay Lobell /
  • Michael W. Rogers /
  • Lindsay A. Rosenwald /
  • Bobby W. Sandage /

Current Share Structure

  • Market Cap: $190,283,118 - 05/16/2018
  • Authorized: 100,000,000 - 05/01/2018
  • Issue and Outstanding: 52,275,582 - 05/01/2018

 


Recent Filings from (NASDAQ: FBIO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 30 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 20 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 13 2018

 

 


Daily Technical Chart for (NASDAQ: FBIO)

Daily Technical Chart for (NASDAQ: FBIO)


Stay tuned for daily updates and more on (NASDAQ: FBIO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: FBIO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FBIO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of FBIO and does not buy, sell, or trade any shares of FBIO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/